.Attributes Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) therapy of individuals along with HER2+ sophisticated breast cancer cells as well as active or even stable human brain metastases showed steady intracranial activity as well as systemic efficacy of T-DXd.